<DOC>
	<DOC>NCT02749513</DOC>
	<brief_summary>The purpose of this study is to demonstrate that orally administered itraconazole, a commonly used antifungal medication, can inhibit Hedgehog pathway signaling in patients with esophageal cancer, including adenocarcinoma (EAC) and squamous cell carcinoma (ESCC).</brief_summary>
	<brief_title>Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>â€¢ Clinical diagnosis of esophageal cancer, including gastroesophageal junction cancer Patients unwilling or unable to provide informed consent Coagulopathy that precludes safe endoscopic/surgical procedure (platelet count &lt;100,000/mm3, INR&gt;1.5) Esophageal varices Comorbidity (e.g. pulmonary, cardiac, renal, or liver disease) that precludes safe participation in the study QTc&gt;450 ms LFT's&gt;3xULN Pregnancy Allergy to itraconazole History of symptomatic congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>